Diarrhoea in a patient with metastatic melanoma:Ipilimumab ileocolitis treated with infliximab

查看全文 作　　者：Rob ME [1]Slangen;Alfonsus JM van den [2]Eertwegh;Adriaan A van [3]Bodegraven;Nanne KH de [3]Boer 机构地区：[1]Department of Gastroenterology and Hepatology,HagaZiekenhuis,2545 CH Den Haag,The Netherlands;[2]Department of Medical Oncology,VU University Medical Centre,1007 MB Amsterdam,The Netherlands;[3]Department of Gastroenterology and Hepatology,VU University Medical Centre,1007 MB Amsterdam,The Netherlands 出　　处：《World Journal of Gastrointestinal Pharmacology and Therapeutics》索引2013年第4卷第3期,共3页 摘　　要：Administration of ipilimumab,a cytotoxic T-lymphocyte associated antigen-4-blocking monoclonal antibody,leads to enhancement of the anti-tumor T-cell respons and as a result shows a significant survival benefit in metastatic melanoma patients.Therefore patients are currently receiving this promising therapy as a secondline strategy.Unfortunately,by activation of the T-cell immune reponse,ipilimumab therapy may lead to an unwanted induction of different autoimmune phenomena.Diarrhoea and colitis occur in up to one third of patients.Here we present a case of ipilimumab induced ileocolitis which was successfully treated with infliximab,an anti-tumor necrosis factor monoclonal antibody,after corticosteroid therapy failure.Although formal trials are lacking,recently publicated series suggest that infusional therapy of infliximab is effective in ipilimumab induced ileocolitis. 关 键 词：Melanoma IPILIMUMAB Colitis INFLIXIMAB CYTOTOXIC T-LYMPHOCYTE associated antigen-4